Evonik now offers EUDRATEC® SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products. This emulsion-based process technology overcomes solubility hurdles that cannot be resolved by existing manufacturing technologies. As more than 70 percent of new small molecules are insoluble, EUDRATEC® SoluFlow therefore enables the development of new oral therapeutics in diverse areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes.
EUDRATEC® SoluFlow complements the Evonik Health Care portfolio of oral drug delivery system solutions, which comprises oral excipients such as EUDRAGIT® functional polymers, the ready-to-fill functional capsules EUDRACAPTM, as well as technologies and services to optimize drug performance.
EUDRATEC® SoluFlow is a technology and service that turns a poorly soluble drug into a free-flowing powder of the amorphous solid dispersion (ASD). This ASD can easily be compressed into tablets or filled into capsules, reducing the number and complexity of post-processing steps. The emulsion-based process uses standard pharma equipment to manufacture uniform microparticles that have a controlled target size and are produced at high yield.